Hangzhou Tigermed Consulting Co., Ltd
300347
Rank in Stocks
#3216
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides... Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People’s Republic of China.
Share Price
$7.44
Market Cap
$5.49B
Change (1 day)
-2.99%
Change (1 year)
-0.42%
Country
CN
Trade Hangzhou Tigermed Consulting Co., Ltd (300347)
Category
Healthcare
Number of shares outstanding for Hangzhou Tigermed Consulting Co., Ltd (300347)
Number of shares outstanding as of June 2026: 836.35M
According to Hangzhou Tigermed Consulting Co., Ltd latest financial reports and stock price the company's current number of shares outstanding is 836.35M. At the end of December 2024 the company had 863.04M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Hangzhou Tigermed Consulting Co., Ltd (300347) from 2009 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 836.35M | -2.04% |
| 2025 | 853.74M | -1.08% |
| 2024 | 863.04M | -0.22% |
| 2023 | 864.95M | -0.69% |
| 2022 | 870.96M | 9.01% |
| 2020 | 798.98M | 7.27% |
| 2019 | 744.81M | -0.63% |
| 2018 | 749.50M | 1.26% |
| 2017 | 740.14M | 5.24% |
| 2016 | 703.26M | 8.00% |
| 2015 | 651.16M | 0.30% |
| 2014 | 649.23M | 1.26% |
| 2013 | 641.15M | 20.16% |
| 2012 | 533.60M | 10.72% |
| 2011 | 481.93M | 1.32% |
| 2010 | 475.64M | 16.86% |
| 2009 | 407.01M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | -69.64% |
US
|
|
| 396.00M | -52.65% |
US
|
|
| 478.91M | -42.74% |
AU
|
|
| 0.00 | -100.00% |
BE
|
|
| 62.19M | -92.56% |
NL
|
